PharmaShots | Incisive News in 3 Shots

Subscribe Now

P-III Trial

GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology

GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology

August 12, 2021

GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology

GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology

August 12, 2021

AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

March 25, 2021

EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer

EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer

March 25, 2021

AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

March 25, 2021

EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer

EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer

March 25, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us